2023 was a troublesome yr to the biopharma business, with various corporations downsizing and restructuring their workforces to remain afloat. There are signs of recovery, as mergers and acquisitions picked up through the pharmaceutical and lifestyle sciences sector while in the latter Component of 2023 and have continued their upswing https://sites.google.com/view/bio-sites/blog